Amgen teams with Immatics on cancer immunotherapies

By Gareth Macdonald contact

- Last updated on GMT

Amgen will manufacture, trial and sell cancer immunotherapies developed in collaboration with Immatics Biotechnologies GmbH under an agreement announced this week.

Immatics will use its target identification capabilities to find Tumor-Associated Peptide (TUMAP) candidates on the surface of cancer cells.

Amgen will then develop bi-specific antibodies which bind both the peptide candidates identified by Immatics and proteins on the surface of T cells. 

Spokeswoman Nikola Wiegeler told us “Immatics is responsible for identifying the targets and specific T cell receptors against those targets. Amgen is responsible for making BiTEs and further development​.”

Amgen will pay Immatics $30m (€28m) upfront and has agreed to provide an additional $500m to Immatics to fund development.

The California, US biotech will also pay royalties on any produced that are commercialized.

US presence

In 2015​ Immatics set up a $60m joint venture (JV) with the University of Texas to develop adoptive cellular therapies (ACT) for cancer.

While the JV – known as Immatics US – was not directly involved in winning the Amgen deal, having a presence in the US did help Immatics showcase its capabilities according to Wiegeler.

The discussions have started separate but the JV has seen very positive responses from various parties including Amgen so it certainly helped awareness to what Immatics is doing​.”

Related news

Related products

show more

A Trusted Resin Provider For Over 35 Years

A Trusted Resin Provider For Over 35 Years

Purolite Life Sciences | 18-Sep-2017

Watch our video above to learn more about the history of Purolite Life Sciences.To discuss how we can assist your journey to process excellence, please...

The Next Stage – Eppendorfs new Mastercycler X50

The Next Stage – Eppendorfs new Mastercycler X50

Eppendorf for Bioprocess – Solutions that grow with you | 05-Sep-2017 | Application Note

The Mastercycler X50 is Eppendorf's new PCR cycler with lots of new benefits. Not only can you heat with 10°C/s, you can also optimize two different...

Related suppliers